Reports Q3 revenue $13.78M vs. $9.11M last year. The company’s cash, cash equivalents and marketable securities as of September 30, 2025, are now expected to fund operations into mid-2027 and through lonvo-z’s anticipated U.S. commercial launch for HAE.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $4 from $9 at Baird
- Intellia Therapeutics: Hold Rating Amid Safety Concerns and Regulatory Challenges
- Intellia Therapeutics price target lowered to $12 from $17 at Wells Fargo
- Intellia Therapeutics price target lowered to $21 from $29 at Citizens JMP
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays